Cure My Disease

Don't miss your cure!

 Log in / Sign up

Olaparib's Real-World impact on BRCA ovarian cancer examined

NCT ID NCT04532645

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked back at medical records of 342 women in Europe with advanced ovarian cancer and a BRCA gene mutation. All had taken the drug olaparib (Lynparza) as their first maintenance treatment after initial chemotherapy. Researchers tracked how long patients lived without their cancer getting worse and overall survival over three years. The goal was to see how well olaparib works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Olaparib (Lynparza)
What this could lead to
If successful, this study could confirm how well olaparib works as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer in real-world settings.
What could go wrong
This is an observational study that looks back at existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

342 people

The number who actually took part.

Started

Jan 2021

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

• Patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer treated with olaparib in first-line maintenance setting

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III - IV) epithelial ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer who have completed first line platinum-based chemotherapy, in PR/CR and treated with at least one dose of olaparib in first line maintenance setting * Patients aged ≥18 years old * Ability and/or willingness to provide a signed informed consent form (where required) Exclusion Criteria: * Withdrawal of informed consent (where consent required) * Concurrent participation in any clinical study with an investigational product at the time of olaparib initiation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA mutated advanced ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovary cancer

Contacts and locations

Locations

  • Research Site

    Avignon, 84918, France

  • Research Site

    Besançon, 25000, France

  • Research Site

    Bordeaux, 33000, France

  • Research Site

    Bourg-en-Bresse, 1012, France

  • Research Site

    Calais, 62100, France

  • Research Site

    Chambray-lès-Tours, 37175, France

  • Research Site

    Epagny Metz-Tessy, 74370, France

  • Research Site

    Grenoble, 38000, France

  • Research Site

    Langon, 33210, France

  • Research Site

    Lyon, 69004, France

  • Research Site

    Nancy, 54000, France

  • Research Site

    Paris, 75014, France

  • Research Site

    Pierre-Bénite, 69310, France

  • Research Site

    Roubaix, 59100, France

  • Research Site

    Saint-Cloud, 92210, France

  • Research Site

    Saint-Grégoire, 35760, France

  • Research Site

    Suresnes, 92150, France

  • Research Site

    Tours, 37000, France

  • Research Site

    Villejuif, 94800, France

  • Research Site

    Acquaviva delle Fonti, 70021, Italy

  • Research Site

    Aviano, 33081, Italy

  • Research Site

    Bari, 70124, Italy

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Cagliari, 09121, Italy

  • Research Site

    Catania, 95126, Italy

  • Research Site

    Florence, 50134, Italy

  • Research Site

    Genova, 16132, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Milan, 20162, Italy

  • Research Site

    Modena, 41124, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Negrar, 37024, Italy

  • Research Site

    Parma, 43126, Italy

  • Research Site

    Roma, 00144, Italy

  • Research Site

    Roma, 00168, Italy

  • Research Site

    Torino, 10128, Italy

  • Research Site

    Birmingham, United Kingdom

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    Ediburgh, United Kingdom

  • Research Site

    Glasgow, United Kingdom

  • Research Site

    Guildford, United Kingdom

  • Research Site

    Leeds, United Kingdom

  • Research Site

    Liverpool, United Kingdom

  • Research Site

    London, EC1A7BE, United Kingdom

  • Research Site

    London, NW12BU, United Kingdom

  • Research Site

    London, SW36JJ, United Kingdom

  • Research Site

    London, W120HS, United Kingdom

  • Research Site

    Maidstone, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Newcastle, United Kingdom

  • Research Site

    Northampton, United Kingdom

  • Research Site

    Nottingham, United Kingdom

  • Research Site

    Portsmouth, United Kingdom

  • Research Site

    Swansea, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.